SOPHiA GENETICS has entered into a new global, multi-year collaboration with AstraZeneca to develop, validate and commercialise two companion diagnostic (CDx) programmes designed to support precision oncology therapies.

Under the agreement, SOPHiA GENETICS will leverage its clinical testing and companion diagnostic capabilities to develop diagnostic solutions intended to identify patients who may be eligible for specific AstraZeneca cancer treatments.

As part of the collaboration, SOPHiA GENETICS will develop its Solid Tumor application into a decentralised companion diagnostic, enabling testing to be performed across laboratories closer to patients. The company will also develop and validate its Hematological Oncology application to support a companion diagnostic programme for patients with blood cancers.

The collaboration aims to combine biomarker detection with decentralised testing capabilities to support faster and broader access to precision oncology treatments. By enabling laboratories in different locations to perform standardised testing, the companies seek to reduce geographic barriers to diagnostic access and help identify appropriate patients for targeted therapies.

Ross Muken, CEO, SOPHiA GENETICS, said, “A breakthrough therapy only matters to the patients we can find in time to treat. We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch. We believe these programmes are what that future looks like in practice.”

SOPHiA GENETICS said its global, data-driven platform can generate insights from patient populations to support clinical decision-making across healthcare systems. The company expects the collaboration to strengthen the connection between diagnostic testing and therapeutic development, while supporting the expansion of precision medicine.

The two companion diagnostic programmes will focus on solid tumours and hematological cancers, with the broader objective of improving patient identification and expanding access to innovative oncology therapies.